<?xml version="1.0" encoding="UTF-8"?>
<p id="p0180">However, it should be noted that umifenovir (arbidol) (
 <bold>7</bold>) seems to be a privileged molecule because this polyfunctionalized indole derivative does not infringe on either the Lipinski-Veber rules or the bioactivity score criteria. It is a pity that information on this drug in COVID-19 treatment is minimally available, and its use against coronavirus is still controversial. Although selected Chinese scientists have asked the WHO to include arbidol in the list of drugs recommended for combating coronavirus, experts have doubts related to the usefulness of this drug, which has not proved its effectiveness in several tests, and tests are still ongoing [
 <xref rid="bib112" ref-type="bibr">112</xref>]. Until now, arbidol has shown efficacy against influenza viruses by targeting the hemagglutinin fusion machinery that suggests stimulation of the immune system or anti-inflammatory action. However, the structural basis of the mechanism underlying fusion inhibition by arbidol has remained obscure [
 <xref rid="bib113" ref-type="bibr">113</xref>].
</p>
